加拿大卫生监管机构已正式批准美国制药巨头礼来公司研发的Kisunla™（Donanemab）用于治疗早期阿尔茨海默病。该突破性疗法的获批为轻度认知障碍患者提供了全新的治疗选择，标志着神经退行性疾病治疗领域取得重要进展。
Donanemab作为靶向淀粉样蛋白斑块的单克隆抗体，通过清除大脑中的β-淀粉样蛋白沉积来延缓疾病进展。临床数据显示，该药物能显著减缓早期阿尔茨海默病患者的认知功能下降速度。此次获批将使加拿大成为全球少数几个批准此类创新疗法的国家之一。
分析师指出，此次监管绿灯将进一步加强礼来在神经科学领域的领导地位，并为其产品管线注入新的增长动力。随着全球老龄化进程加速，阿尔茨海默病治疗市场预计将呈现指数级增长，这款新药的商业前景备受市场关注。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.